Please login to the form below

AMR

This page shows the latest AMR news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Europe launches antimicrobial research ‘Accelerator’. A new Antimicrobial Resistance (AMR) Accelerator Programme has been unveiled by the EU and pharma-funded Innovative Medicines Initiative (IMI).

Latest news

Evotec says Sanofi deal makes it anti-infectives powerhouse

regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.” It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria,
Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

AMR. UK pledges £30m to fight antimicrobial resistance. The UK has taken a lead in co-ordinating international action to counter antimicrobial resistance in the last few years, and has just ... A further £5m will be spent on a partnership with
Profit: the ugly, dirty truth?

On anti-microbial resistance (AMR), the incentive structures offered up by governments globally so far have lacked ambition and fundamental insight into how the market drives pharma to invest and take ... We have a global declaration on AMR, which has a
Sanofi taps Evotec for new anti-infectives drive

Earlier this year, an independent report looking at the pharma industry’s efforts to tackle antimicrobial resistance (AMR) said the sector is still not on track to avert a potential healthcare
Pharma must do more on antibiotic resistance, Davos meeting hears

The benchmark study reveals that GlaxoSmithKline (GSK) and Johnson &Johnson (J&J) are leading the charge against AMR among 30 companies active in new antimicrobial research. ... for AMR and bring them to market responsibly,” citing the case of J&J’s

More from news
Approximately 5 fully matching, plus 15 partially matching documents found.

Latest Intelligence

Rules of engagement

Only one-fifth were aware of its abbreviated form ‘AMR’. By contrast, more than two-thirds knew of the terms ‘antibiotic resistance’ or ‘drug resistance’.
The threat of antimicrobial resistance

Why this issue is such a fundamental challenge. A look at some of the headline statistics on the antimicrobial resistance (AMR) issue is particularly sobering. ... market. About the AMR Centre. The AMR Centre is a key part of the UK’s response to the
The AMR threat

The roots of the AMR problem lay in over-prescribing and the use of antibiotics for growth promotion in the agricultural sector outside Europe. ... Given the strength of the government's backing for the fight against AMR, the Review can certainly claim
Cubist: Meeting the challenge in antibiotics

AMR is something that is increasing and it doesn't stop at borders - we see big resistance problems in Europe. ... Several other companies are signed up to the IMI's efforts in AMR, including GlaxoSmithKline, AstraZeneca, Janssen and Sanofi, suggesting

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Antibiotic Resistance: Alarm bells ring louder than ever

where antibiotics and the threat of antimicrobial resistance (AMR) became a hot topic in the mainstream media. ... How can this be prevented? AMR is a complex, global issue and corrective action is only possible if we accurately know and understand what
amr

amr is a full-service market research agency and we are passionate about the research that we do.